The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Relapse after HSCT 2021 | The use of targeted therapy to prevent relapse post-transplant
Mark Levis, MD, PhD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the use of targeted agents to prevent relapse post-transplantation. Several lines of evidence have indicated that targeted therapy is not effective for this purpose. In addition, the long-term toxicity of targeted agents used for maintenance therapy is unknown. Dr Levis comments on the use of FLT3 inhibitors, which have been shown to improve long-term survival for patients with FLT3-mutated acute myeloid leukemia (AML), and discusses a randomized study which is currently investigating the effects of treatment with FLT3 inhibitors versus placebo, with the aim of identifying patients at a greater risk of relapse, and thus at a greater need of maintenance therapy. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
